Cocrystal Pharma Inc. has published a new investor presentation outlining its ongoing efforts in developing broad-spectrum antiviral drugs targeting influenza, norovirus, coronavirus, and respiratory viruses. The company highlights its proprietary structure-based drug discovery platform, which enables the design of antiviral candidates aimed at highly conserved viral regions. Key drug candidates in development include the oral pan-viral protease inhibitor CDI-988 for both norovirus and coronavirus infections, and the PB2 inhibitor CC-42344 for influenza A, currently in Phase 2a clinical trials. Cocrystal also notes the completion of GLP toxicology studies for certain assets and continues to explore government contract opportunities for pandemic preparedness. The company reports that its drug discovery platform may facilitate expedited regulatory pathways for its antiviral candidates. You can access the full presentation through the link below. https://www.cocrystalpharma.com